Clinical trial
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients…
NCT00209989 · Institut Claudius Regaud, Other · Completed
Key facts
| NCT number | NCT00209989 |
|---|---|
| Title | Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme |
| Official title | Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme |
| Lead sponsor | Institut Claudius Regaud, Other |
| Collaborators | Janssen-Cilag Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug, Procedure |
| Interventions | Zarnestra, standard Radiation therapy |
| Enrollment | 27 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 24, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: